Skip to main content
SpringerLink
Log in

Quality of Life Assessment in the Adjuvant Setting: Is It Relevant?

  • Conference paper
Adjuvant Therapy of Primary Breast Cancer VI

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 152))

Abstract

In this paper we address a question concerning quality-of-life assessment in the adjuvant setting: is it relevant? Like the science of quality-of-life evaluation itself, the answer to this question is multifaceted. The most direct answer is yes, but only if there is a well-defined question of importance for patient care. This requires a specific hypothesis and an appropriate methodology to test it.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Senn H-J, Rudenstam C-M for the International Breast Cancer Study Group (IBCSG) (1997) Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. Ann Oncol 8:825–835

    Article  PubMed  CAS  Google Scholar 

  • Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, Forbes JF for the Australia New Zealand Breast Cancer Study Group (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol 10:1833–1838

    PubMed  CAS  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1–15, 71-85

    Google Scholar 

  • EuroQol Group (1990) EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 16:199–208

    Article  Google Scholar 

  • Feeny D, Furlong W, Boyle M, Torrance GW (1995) Multi-attribute health status classification systems. Pharmacoeconomics 7:490–503

    Article  PubMed  CAS  Google Scholar 

  • Fetting J, Gray R, Abeloff MD, Fowble B, Smith T., Vail S et al (1995) CAF vs. a 16 week multidrug regimen as adjuvant therapy for receptor-negative, node-positive breast cancer: an Intergroup study. Proc Am Soc Clin Oncol 114:96

    Google Scholar 

  • Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673–1682

    Article  PubMed  CAS  Google Scholar 

  • Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE (1998) Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol 16:501–514

    PubMed  CAS  Google Scholar 

  • Gelber RD, Goldhirsch A, Cavalli F for the International Breast Cancer Study Group (1991) Quality-of-life-adjusted evaluation of a randomized trial comparing adjuvant therapies for operable breast cancer. Ann Intern Med 114:621–628

    PubMed  CAS  Google Scholar 

  • Gelber RD, Goldhirsch A, Hürny C, Bernhard J, Simes RJ for the International Breast Cancer Study Group (1992) Quality of life in clinical trials of adjuvant therapies. J Natl Cancer Inst Monogr 11:127–135

    PubMed  Google Scholar 

  • Gelber RD, Cole BF, Gelber S, Goldhirsch A (1995) The Q-TWiST method. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd ed). Raven, New York; pp 427–435

    Google Scholar 

  • Glasziou PP, Simes RJ, Gelber RD (1990) Quality adjusted survival analysis. Stat Med 9:1259–1276

    Article  PubMed  CAS  Google Scholar 

  • Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates A for the Ludwig Breast Cancer Study Group (1989) Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7:36–44

    PubMed  CAS  Google Scholar 

  • Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M, Gelber RD for the International Breast Cancer Study Group (1998) Adjuvant chemoendocrine therapy in postme-nopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. J Clin Oncol 16:1358–1362

    PubMed  CAS  Google Scholar 

  • Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S et al (1998) Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (bc). Proc Am Soc Clin Oncol 17:101a

    Google Scholar 

  • Hürny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam C-M, Simoncini E, Crivellari D, Goldhirsch A, Senn H-J for the International Breast Cancer Study Group (1996) Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 347:1279–1284

    PubMed  Google Scholar 

  • International Breast Cancer Study Group (1997) Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15:1385–1394

    CAS  Google Scholar 

  • Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948) The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1:634

    Article  Google Scholar 

  • Levine M, Bramwell V, Pritchard KI et al (1998) A randomized trial of cyclophosphamide, epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, fluorouracil in premenopausal women with node positive breast cancer. J Clin Oncol (in press).

    Google Scholar 

  • Lindley C, Vasa S, Sawyer WT, Winer ET (1998) Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. Cancer 16:1380–1387

    CAS  Google Scholar 

  • Simes RJ, Cocker K, Glasziou P et al (1989) Costs and benefits of adjuvant chemotherapy for breast cancer: an assessment of patient preferences. Proc Am Soc Clin Oncol 8:52A

    Google Scholar 

  • Torrance GW, Furlong W, Boyle M, Torrance EW (1995) Multi-attribute preference functions. Pharmacoeconomics 7:503–520

    Article  PubMed  CAS  Google Scholar 

  • Weeks J, O’Leary J, Fairclough D, Paltiel D, Weinstein M (1994) The “Q-tility Index”: a new tool for assessing health-related quality of life and utilities in clinical trials and clinical practice. Proc Am Soc Clin Oncol 13:426

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA, 02115, USA

    R. D. Gelber & M. Bonetti

  2. Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA

    R. D. Gelber & M. Bonetti

  3. Department of Community and Family Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA

    B. F. Cole

  4. Frontier Science and Technology Research Foundation, Brookline, Massachusetts, USA

    R. D. Gelber & S. Gelber

  5. Department of Medical Oncology and Radiation Oncology, European Institute of Oncology, Milan, Italy

    A. Goldhirsch

  6. Department of Medical Oncology, Ospedale Civico, Lugano, Switzerland

    A. Goldhirsch

  7. International Breast Cancer Study Group, Bern, Switzerland

    A. Goldhirsch

Authors
  1. R. D. Gelber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Bonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. F. Cole
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Gelber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Goldhirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum für Tumordiagnostik und Prävention, Rorschacherstrasse 150, CH-9006, St. Gallen, Switzerland

    Hans-Jörg Senn

  2. Dana Farber Cancer Institute Biostatistics, 44 Binney Street, Boston, 02115, USA

    Richard D. Gelber Ph.D

  3. Ospedale Civico, CH-6900, Lugano, Switzerland

    Aron Goldhirsch

  4. Klinik C für Innere Medizin Abteilung für Onkologie und Hämatologie, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland

    Beat Thürlimann

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Gelber, R.D., Bonetti, M., Cole, B.F., Gelber, S., Goldhirsch, A. (1998). Quality of Life Assessment in the Adjuvant Setting: Is It Relevant?. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Primary Breast Cancer VI. Recent Results in Cancer Research, vol 152. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45769-2_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-45769-2_36

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-45771-5

  • Online ISBN: 978-3-642-45769-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation